Table 3.
Premenopausal N = 142 | Postmenopausal N = 594 | |||||
---|---|---|---|---|---|---|
PRLR staining (negative or low) N (%) | PRLR staining (strong) N (%) | p Value | PRLR staining (negative or low) N (%) | PRLR staining (strong) N (%) | p Value* | |
PRL serum levels** N = 349 | ||||||
Low | 5 (17.9) | 23 (82.1) | 25 (17.9) | 115 (82.1) | ||
High | 7 (23.3) | 23 (76.7) | 0.61 | 23 (15.5) | 125 (84.5) | 0.60 |
Histological type N = 713 | ||||||
Ductal | 27 (22.3) | 94 (77.7) | 79 (16.7) | 394 (83.3) | ||
Lobular | 1 (7.1) | 13 (92.7) | 0.30 | 16 (15.2) | 89 (84.8) | 0.71 |
Axillary node metastasis N = 716 | ||||||
Node negative | 13 (19.7) | 53 (80.3) | 49 (14.9) | 280 (85.1) | ||
Node positive | 15 (20.6) | 58 (79.5) | 0.90 | 45 (18.2) | 203 (81.9) | 0.30 |
ER N = 732 | ||||||
Negative | 12 (19.7) | 49 (80.3) | 38 (20.2) | 150 (79.8) | ||
Positive | 17 (21.3) | 63 (78.8) | 0.82 | 59 (14.6) | 344 (85.4) | 0.09 |
PR N = 731 | ||||||
Negative | 14 (22.2) | 49 (77.8) | 56 (17.6) | 262 (82.4) | ||
Positive | 15 (19.2) | 63 (80.8) | 0.66 | 41 (15.1) | 231 (84.9) | 0.41 |
HER2 N = 721 | ||||||
Negative | 25 (20.5) | 97 (79.5) | 79 (15.3) | 437 (84.7) | ||
Positive | 4 (22.2) | 14 (77.8) | 1.0 | 16 (24.6) | 49 (75.4) | 0.06 |
ER/PR N = 730 | ||||||
ER+ PR+ | 13 (20.3) | 51 (79.7) | 36 (14.4) | 214 (85.6) | ||
ER+ PR− | 4 (25.0) | 12 (75.0) | 23 (15.1) | 129 (84.9) | ||
ER− PR+ | 2 (14.3) | 12 (85.7) | 5 (22.7) | 17 (77.3) | ||
ER− PR− | 10 (21.3) | 37 (78.7) | 0.99 | 33 (20.0) | 132 (80.0) | 0.11 |
ER/PR/HER2 N = 721 | ||||||
ER+ or PR+ and HER2− | 18 (19.6) | 74 (80.4) | 60 (14.6) | 351 (85.4) | ||
ER+ or PR+ and HER2+ | 1 (50.0) | 1 (50.0) | 4 (33.3) | 8 (66.7) | ||
ER− and PR− and HER2+ | 2 (16.7) | 10 (83.3) | 7 (17.5) | 33 (82.5) | ||
ER− and PR− and HER2− | 8 (24.2) | 25 (75.8) | 0.64 | 24 (20.2) | 95 (79.8) | 0.13 |
Not all strata sum to 100 % due to rounding
* p Values from χ 2 test
**Category for PRL levels assigned using median PRL levels for the subset of cases with this measurement